Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9627-9637

  Shi, Wenna ^a   Lihui, Su ^a   Li, Qianqian ^b   Sun, Lidan ^c   Lv, Jing ^a   Li, Jun ^a   Cheng, Baoquan ^a  

^a SHANDONG UNIVERSITY   (China)

^b Rushan People s Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; High mobility group box1; Nuclear factor kappaB P65; Toll like receptor 2

Indexed keywords

SMALL INTERFERING RNA; TLR2 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 2;

APOPTOSIS; CELL MOTION; CELL PROLIFERATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 2; TRANSFECTION;

EID: 84922392512     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2268-3     Document Type: Article

References (31)

1. Hiwatashi K, Ueno S, Abeyama K, et al. A novel functions of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol. 2007;15:923–33.
2. Stewart BW, Kleihues P, editors. World cancer report. Lyon: IARC Press; 2003.
3. Yang XJ, Zhang YC, Zhang LY. Silencing α-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 2008;271:281–93.
4. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457:426–33.
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–76.
6. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118: 229–41.
7. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A. 2005;102:99–104.
8. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006;131:862–77.
9. Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol. 2006;290:1318–28.
10. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007;67:4346–52.
11. Muccioli M, Sprague L, Nandigam H, Pate M, Benencia F. Toll-like receptors as novel therapeutic targets for ovarian cancer. ISRN Oncol. 2012;64:21–41.
12. Hassan F, Islam S, Tumurkhuu G, et al. Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer. 2006;6:281–8.
13. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 2007;67:774–81.
14. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active toll-like receptor 9. Respir Res. 2005;6:1–19.
15. Molteni M, Marabella D, Orlandi C, Rossetti C. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett. 2006;235:75–83.
16. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176:4894–901.
17. Ren T, Wen ZK, Liu ZM, et al. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther. 2007;6:1704–9.
18. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–6.
19. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013;3(1):1–20.
20. Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72:3290–301.
21. Lee H, Park M, Shin N, et al. High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells. Biochem Biophys Res Commun. 2012;424:321–6.
22. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8:195–202.
23. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91–9.
24. Thompson AJ, Colledge D, Rodgers S, et al. Stimulation of the interleukin-1 receptor and toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther. 2009;14:797–808.
25. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2006;16(1):32–7.
26. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface toll-like receptors. Semin Immunol. 2007;19(1):3–10.
27. Kosovo N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell. 2010;337:251–8.
28. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40(6):446–52.
29. Jiang W, Wang ZM, Fan XG, et al. Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci. 2012;57:92–8.
30. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev. 2004;4: 499–511.
31. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med. 2005;11:1173–9.